Ā | DLBCL | PMBCL | p_value (Ļ2 test) | ||
---|---|---|---|---|---|
Others | MYD88_L265P | JAK2/PD-L2_amp | |||
Patients | 53 (65.43%) | 15 (18.52%) | 8 (9.88%) | 5 (6.17%) | Ā |
Age | 0.003* | ||||
āmedian (range) | 57 (23ā80) | 57 (31ā88) | 47 (27ā70) | 27 (19ā36) | Ā |
BM | 0.520 | ||||
āNegative | 46 (86.79%) | 14 (93.33%) | 8 (100.00%) | 5 (100.00%) | Ā |
āPositive | 7 (13.21%) | 1 (6.67%) | 0 (00.00%) | 0 (00.00%) | Ā |
IHC Hansā algorithm | 0.806 | ||||
āGCB | 16 (30.19%) | 3 (20.00%) | 2 (25.00%) | 2 (40.00%) | Ā |
āNon-GCB | 37 (69.81%) | 12 (80.00%) | 6 (75.00%) | 3 (60.00%) | Ā |
IPI | 0.522 | ||||
āLow-risk | 26 (49.06%) | 7 (46.67%) | 2 (25.00%) | 4 (80.00%) | Ā |
āLow_intermediate | 12 (22.64%) | 5 (33.33%) | 3 (37.50%) | 0 (00.00%) | Ā |
āHigh_intermediate | 7 (13.21%) | 3 (20.00%) | 2 (25.00%) | 1 (20.00%) | Ā |
āHigh | 8 (15.09%) | 0 (00.00%) | 1 (12.50%) | 0 (00.00%) | Ā |
MYC Breakapart | 0.822 | ||||
āNegative | 50 (94.34%) | 14 (93.33%) | 7 (87.50%) | 5 (100.00%) | Ā |
āPositive | 3 (05.66%) | 1 (06.67%) | 1 (12.50%) | 0 (00.00%) | Ā |